Amylyx Pharmaceuticals Management
Management criteria checks 3/4
Amylyx Pharmaceuticals' CEO is Josh Cohen, appointed in Jan 2013, has a tenure of 12.42 years. total yearly compensation is $6.50M, comprised of 10.6% salary and 89.4% bonuses, including company stock and options. directly owns 3.76% of the company’s shares, worth $18.19M. The average tenure of the management team and the board of directors is 4.4 years and 4.3 years respectively.
Key information
Josh Cohen
Chief executive officer
US$6.5m
Total compensation
| CEO salary percentage | 10.56% |
| CEO tenure | 12.4yrs |
| CEO ownership | 3.8% |
| Management average tenure | 4.4yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
May 10
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Apr 03
Avexitide Launch In 2027 Will Strengthen Our Pipeline
Strategic developments in the pipeline and collaborations aim to address unmet medical needs and present long-term revenue growth opportunities.Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Feb 24Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
Dec 19Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
Dec 10Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Nov 25There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Nov 04Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Sep 18Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Jun 25Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Apr 25Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$219m |
| Dec 31 2024 | US$6m | US$686k | -US$302m |
| Sep 30 2024 | n/a | n/a | -US$259m |
| Jun 30 2024 | n/a | n/a | -US$166m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | US$7m | US$621k | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Compensation vs Market: Josh's total compensation ($USD6.50M) is above average for companies of similar size in the US market ($USD2.67M).
Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.
CEO
Josh Cohen (33 yo)
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.4yrs | US$6.50m | 3.76% $ 18.2m | |
| Co-Founder | 12.4yrs | US$6.50m | 3.76% $ 18.2m | |
| Chief Financial Officer | 4.4yrs | US$2.54m | 0.36% $ 1.7m | |
| Chief Legal Officer & General Counsel | 3.3yrs | US$2.30m | 0.055% $ 264.6k | |
| Chief Technical Operations Officer | no data | no data | no data | |
| Head of Investor Relations & Communications | no data | no data | no data | |
| Chief Human Resources Officer | 1.3yrs | no data | no data | |
| Global Head of Regulatory Affairs | 4.8yrs | no data | no data | |
| VP & Head of Global Medical Affairs | 5.1yrs | no data | no data | |
| Head of Global Medical Strategy & Communications | no data | no data | no data | |
| Chief Medical Officer | 1.6yrs | US$2.37m | 0.055% $ 267.0k | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: AMLX's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.4yrs | US$6.50m | 3.76% $ 18.2m | |
| Co-Founder | 11.4yrs | US$6.50m | 3.76% $ 18.2m | |
| Special Advisor & Member of Advisory Board | 4.4yrs | US$51.24k | no data | |
| Independent Chairman of the Board | 10.4yrs | US$143.33k | 0.93% $ 4.5m | |
| Chairman of The Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | US$87.70k | 0.062% $ 298.1k | |
| Independent Director | 4yrs | US$100.20k | 0.0056% $ 27.1k | |
| Independent Director | 1.3yrs | US$159.85k | 0.011% $ 54.2k | |
| Independent Director | 4.3yrs | US$94.15k | 0.0044% $ 21.4k |
Experienced Board: AMLX's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/12 22:09 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amylyx Pharmaceuticals, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Timothy Anderson | BofA Global Research |
| Neena Bitritto-Garg | Citigroup Inc |